Summary
Bristol-Myers Squibb Company (BMY) filed an 8-K on July 29, 2004, to report its financial results for the second quarter of 2004. The filing incorporates by reference a press release (Exhibit 99.1) detailing these results, along with supplemental financial information (Exhibit 99.2) not included in the press release. Investors should refer to these exhibits for specific financial performance metrics, including revenues, earnings, and any other significant financial developments during the quarter. The primary purpose of this 8-K is to provide timely disclosure of the company's operational and financial condition. While the 8-K itself doesn't contain the detailed financial figures, it serves as the official notification and gateway to the detailed financial reports that are crucial for understanding the company's performance and making informed investment decisions. Investors are encouraged to review both the press release and the supplemental information for a comprehensive understanding of BMY's second-quarter 2004 financial standing.
Key Highlights
- 1Bristol-Myers Squibb filed an 8-K on July 29, 2004.
- 2The filing announces the company's financial results for the second quarter of 2004.
- 3Exhibit 99.1 is a press release containing the Q2 2004 financial results.
- 4Exhibit 99.2 provides supplemental financial information not included in the press release.
- 5The report is filed under Item 7 (Financial Statements and Exhibits), Item 9 (Regulation FD Disclosure), and Item 12 (Results of Operations and Financial Condition).
- 6The filing ensures timely disclosure of financial performance and operational status to investors.
- 7Investors need to review the attached exhibits for detailed financial performance data.